Research Analysts Offer Predictions for NKTR Q2 Earnings

Key Points

• Analysts at Zacks Research have increased their Q2 2026 earnings per share estimate for Nektar Therapeutics from ($3.26) to ($3.05), with a full-year FY2026 estimate of ($15.25) EPS.
• Nektar Therapeutics reported a loss of ($2.95) EPS in its last quarterly earnings, surpassing analysts' expectations of ($3.13) by $0.18, with revenues of $11.18 million.
• The current consensus rating for Nektar Therapeutics is a "Moderate Buy" with a target price of $88.33, following positive updates from multiple equity analysts.

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Analysts at Zacks Research upped their Q2 2026 earnings per share estimates for Nektar Therapeutics in a report released on Thursday, September 4th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of ($3.05) per share for the quarter, up from their prior estimate of ($3.26). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q3 2026 earnings at ($4.72) EPS, Q4 2026 earnings at ($4.64) EPS, FY2026 earnings at ($15.25) EPS, Q1 2027 earnings at ($3.42) EPS, Q2 2027 earnings at ($3.52) EPS and FY2027 earnings at ($18.26) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) EPS for the quarter, beating the consensus estimate of ($3.13) by $0.18. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%.The business had revenue of $11.18 million for the quarter, compared to analyst estimates of $9.42 million.

Several other equities analysts have also commented on the company. Wall Street Zen lowered Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. HC Wainwright upped their price target on Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a research note on Tuesday, June 24th. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. B. Riley upped their price target on Nektar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Finally, BTIG Research increased their target price on Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $88.33.

Nektar Therapeutics Stock Up 11.7%

Shares of Nektar Therapeutics stock opened at $40.18 on Monday. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $40.45. The business's fifty day simple moving average is $25.78 and its 200-day simple moving average is $16.37. The firm has a market cap of $764.22 million, a PE ratio of -4.57 and a beta of 1.05.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new stake in Nektar Therapeutics in the 4th quarter valued at about $130,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Nektar Therapeutics in the 1st quarter valued at about $41,000. Wellington Management Group LLP raised its position in Nektar Therapeutics by 10.4% in the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock valued at $486,000 after purchasing an additional 49,319 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in Nektar Therapeutics by 267.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 175,193 shares of the biopharmaceutical company's stock valued at $163,000 after purchasing an additional 127,459 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Nektar Therapeutics by 23.3% in the 1st quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after purchasing an additional 41,948 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 1,573 shares of the stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $26.59, for a total transaction of $41,826.07. Following the transaction, the chief executive officer owned 69,340 shares of the company's stock, valued at approximately $1,843,750.60. This represents a 2.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 4,959 shares of company stock worth $138,917. 3.71% of the stock is currently owned by corporate insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.